Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Leukocyte cell therapy - Enlivex Therapeutics

Next Previous
Drug Profile

Leukocyte cell therapy - Enlivex Therapeutics

Alternative Names: Allocetra; Allocetra-OTS; ApoCell; Haematopoitetic-stem-cell-therapy-Enlivex-Therapeutics; OTS-Allocetra

Latest Information Update: 29 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hadassah Medical Organization
  • Developer Enlivex Therapeutics; Hadassah Medical Organization
  • Class Anti-infectives; Anti-inflammatories; Cell therapies
  • Mechanism of Action Cell replacements; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Graft-versus-host disease; Inflammation
  • Phase I Multiple organ failure
  • Preclinical Gout; Multiple sclerosis; Rheumatoid arthritis; Solid tumours
  • No development reported Crohn's disease; Transplant rejection

Most Recent Events

  • 18 Nov 2019 Enlivex Therapeutics completes enrolment in its phase Ib P-SOFA-1 trial for Severe sepsis in Israel (NCT03925857)
  • 04 Nov 2019 Interim adverse events and efficacy data from a phase I clinical trials in Multiple organ failure released by Enlivex Therapeutics
  • 10 Oct 2019 Pharmacodynamics data from a preclinical trial in Multiple organ failure released by Enlivex Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top